Harris, Julen N.
Mauro, Christine
Andresen, Jane A.
Zimet, Gregory D.
Rosenthal, Susan L.
Funding for this research was provided by:
Merck (60472)
Article History
Received: 9 September 2021
Accepted: 29 March 2022
First Online: 29 April 2022
Declarations
:
: Julen Harris, Christine Mauro and Jane Andresen have no conflicts of interest to declare. Gregory Zimet has served as an external advisory board member for Merck and Moderna, and as a consultant to Merck. He also has received investigator-initiated research funding from Merck administered through Indiana University and serves as an unpaid member of the Board of Directors for the Unity Consortium, a non-profit organization that supports adolescent health through vaccination. Susan Rosenthal has received investigator-initiated research funding from Merck Investigator Studies Program administered through Columbia University Irving Medical Center.
: All participants in this study are members of the IPSOS KnowledgePanel®. Participants received an information sheet for this study, and completion of the questionnaire indicated consent.
: There is no potentially identifiable data presented, and in fact, the authors only had access to de-identified data.
: Approval was obtained from the Institutional Review Board of Columbia University Irving Medical Center on December 22, 2020. (IRB-AAAT5154).
Free to read: This content has been made available to all.